J Alfred Witjes1, Thierry Lebret2, Eva M Compérat3, Nigel C Cowan4, Maria De Santis5, Harman Maxim Bruins6, Virginia Hernández7, Estefania Linares Espinós8, James Dunn9, Mathieu Rouanne2, Yann Neuzillet2, Erik Veskimäe10, Antoine G van der Heijden6, Georgios Gakis11, Maria J Ribal12. 1. Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. Electronic address: Fred.Witjes@radboudumc.nl. 2. Hôpital Foch, Department of Urology, University of Versailles-Saint-Quentin-en-Yvelines, Suresnes, France. 3. Department of Pathology, Hôpital La Pitié Salpetrière, UPMC, Paris, France. 4. Radiology Department, Queen Alexandra Hospital, Portsmouth, UK. 5. University of Warwick, Cancer Research Unit, Coventry, UK; Queen Elizabeth Hospital, Birmingham, UK. 6. Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. 7. Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain. 8. Department of Urology, Hospital Universitario Infanta Sofia, Madrid, Spain. 9. Department of Urology, Derriford Hospital, Plymouth, UK. 10. Department of Urology, Tampere University Hospital, Tampere, Finland. 11. Department of Urology, Eberhard-Karls University, Tübingen, Germany. 12. Department of Urology, Hospital Clinic, University of Barcelona, Barcelona, Spain.
Abstract
CONTEXT: Invasive bladder cancer is a frequently occurring disease with a high mortality rate despite optimal treatment. The European Association of Urology (EAU) Muscle-invasive and Metastatic Bladder Cancer (MIBC) Guidelines are updated yearly and provides information to optimise diagnosis, treatment, and follow-up of this patient population. OBJECTIVE: To provide a summary of the EAU guidelines for physicians and patients confronted with muscle-invasive and metastatic bladder cancer. EVIDENCE ACQUISITION: An international multidisciplinary panel of bladder cancer experts reviewed and discussed the results of a comprehensive literature search of several databases covering all sections of the guidelines. The panel defined levels of evidence and grades of recommendation according to an established classification system. EVIDENCE SYNTHESIS: Epidemiology and aetiology of bladder cancer are discussed. The proper diagnostic pathway, including demands for pathology and imaging, is outlined. Several treatment options, including bladder-sparing treatments and combinations of treatment modalities (different forms of surgery, radiation therapy, and chemotherapy) are described. Sequencing of these modalities is discussed. Potential indications and contraindications, such as comorbidity, are related to treatment choice. There is a new paragraph on organ-sparing approaches, both in men and in women, and on minimal invasive surgery. Recommendations for chemotherapy in fit and unfit patients are provided including second-line options. Finally, a follow-up schedule is provided. CONCLUSIONS: The current summary of the EAU Muscle-invasive and Metastatic Bladder Cancer Guidelines provides an up-to-date overview of the available literature and evidence dealing with diagnosis, treatment, and follow-up of patients with metastatic and muscle-invasive bladder cancer. PATIENT SUMMARY: Bladder cancer is an important disease with a high mortality rate. These updated guidelines help clinicians refine the diagnosis and select the appropriate therapy and follow-up for patients with metastatic and muscle-invasive bladder cancer.
CONTEXT: Invasive bladder cancer is a frequently occurring disease with a high mortality rate despite optimal treatment. The European Association of Urology (EAU) Muscle-invasive and Metastatic Bladder Cancer (MIBC) Guidelines are updated yearly and provides information to optimise diagnosis, treatment, and follow-up of this patient population. OBJECTIVE: To provide a summary of the EAU guidelines for physicians and patients confronted with muscle-invasive and metastatic bladder cancer. EVIDENCE ACQUISITION: An international multidisciplinary panel of bladder cancer experts reviewed and discussed the results of a comprehensive literature search of several databases covering all sections of the guidelines. The panel defined levels of evidence and grades of recommendation according to an established classification system. EVIDENCE SYNTHESIS: Epidemiology and aetiology of bladder cancer are discussed. The proper diagnostic pathway, including demands for pathology and imaging, is outlined. Several treatment options, including bladder-sparing treatments and combinations of treatment modalities (different forms of surgery, radiation therapy, and chemotherapy) are described. Sequencing of these modalities is discussed. Potential indications and contraindications, such as comorbidity, are related to treatment choice. There is a new paragraph on organ-sparing approaches, both in men and in women, and on minimal invasive surgery. Recommendations for chemotherapy in fit and unfit patients are provided including second-line options. Finally, a follow-up schedule is provided. CONCLUSIONS: The current summary of the EAU Muscle-invasive and Metastatic Bladder Cancer Guidelines provides an up-to-date overview of the available literature and evidence dealing with diagnosis, treatment, and follow-up of patients with metastatic and muscle-invasive bladder cancer. PATIENT SUMMARY:Bladder cancer is an important disease with a high mortality rate. These updated guidelines help clinicians refine the diagnosis and select the appropriate therapy and follow-up for patients with metastatic and muscle-invasive bladder cancer.
Authors: Johannes Salem; Pia Paffenholz; Christian Bolenz; Melanie von Brandenstein; Angelika Cebulla; Axel Haferkamp; Timur Kuru; Cheryl T Lee; David Pfister; Igor Tsaur; Hendrik Borgmann; Axel Heidenreich Journal: J Cancer Educ Date: 2019-04 Impact factor: 2.037
Authors: Stephen B Williams; Yong Shan; Usama Jazzar; Hemalkumar B Mehta; Jacques G Baillargeon; Jinhai Huo; Anthony J Senagore; Eduardo Orihuela; Douglas S Tyler; Todd A Swanson; Ashish M Kamat Journal: JAMA Surg Date: 2018-10-01 Impact factor: 14.766
Authors: Eva Compérat; Marek Babjuk; Ferran Algaba; Mahul Amin; Fadi Brimo; David Grignon; Donna Hansel; Ondra Hes; Bernard Malavaud; Victor Reuter; Theo van der Kwast Journal: World J Urol Date: 2018-09-14 Impact factor: 4.226
Authors: M Grabbert; T Grimm; A Buchner; A Kretschmer; M Apfelbeck; G Schulz; F Jokisch; B-S Schneevoigt; C G Stief; A Karl Journal: Int Urol Nephrol Date: 2017-09-12 Impact factor: 2.370